Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)-Reference-Cited by-同舟云学术

Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)

Published:2018-08-10 Issue:15 Volume:2 Page:1969-1979
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Daak Ahmed A.¹^ORCID,Dampier Carlton D.²,Fuh Beng³,Kanter Julie⁴,Alvarez Ofelia A.⁵,Black L. Vandy⁶,McNaull Melissa A.⁷,Callaghan Michael U.⁸,George Alex⁹,Neumayr Lynne¹⁰,Hilliard Lee M.¹¹,Sancilio Fredrick¹,Rabinowicz Adrian L.¹,Heeney Matthew M.¹²^ORCID

Affiliation:

1. Sancilio Pharmaceuticals Company, Inc., Riviera Beach, FL;

2. Division of Hematology/Oncology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA;

3. Department of Pediatrics, East Carolina University, Greenville, NC;

4. Division Hematology-Oncology, Department of Pediatrics, Medical University of South Carolina, Charleston, SC;

5. Division of Hematology/Oncology, Department of Pediatrics, University of Miami, Miami, FL;

6. Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Florida College of Medicine, Gainesville, FL;

7. Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, University of Mississippi Medical Center, Jackson, MS;

8. Children’s Hospital of Michigan, Detroit, MI;

9. Texas Children’s Hospital, Houston, TX;

10. Benioff Children’s Hospital, University of California, San Francisco, Oakland, CA;

11. Division of Pediatric Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL; and

12. Division of Hematology/Oncology, Department of Pediatrics, Boston Children’s Hospital, Harvard Medical School, Boston, MA

Abstract

Key Points SC411 increases DHA in blood cell membranes and reduces home-managed SCD pain crisis and analgesic and opioid use at home to treat SCD pain. The rate of sickle cell crisis was 53% lower for the pooled active groups vs placebo.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/2/15/1969/881619/advances021444.pdf

Reference62 articles.

1. Sickle cell disease;Piel;N Engl J Med,2017

2. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions;Piel;PLoS Med,2013

3. Population estimates of sickle cell disease in the U.S;Hassell;Am J Prev Med,2010

4. Effect of a comprehensive clinical care program on disease course in severely ill children with sickle cell anemia in a sub-Saharan African setting;Rahimy;Blood,2003

5. Abnormal haemoglobins in the Sudan savanna of Nigeria. III. Malaria, immunoglobulins and antimalarial antibodies in sickle cell disease;Molineaux;Ann Trop Med Parasitol,1979

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel therapeutic approaches in thalassemias, sickle cell disease, and other red cell disorders;Blood;2024-08-22

2. Current and emerging drug treatment strategies to tackle sickle cell anemia;Expert Opinion on Emerging Drugs;2024-07-22

3. Epeleuton, a novel synthetic ω-3 fatty acid, reduces the hypoxia/reperfusion stress in a mouse model of sickle cell disease;Haematologica;2023-12-14

4. Using disease-modifying therapies in sickle cell disease;Hematology;2023-12-08

5. Response to Letter to Editor;Prostaglandins, Leukotrienes and Essential Fatty Acids;2023-12